

## Committee Print

(SHOWING THE TEXT OF H.R. 1193, AS FAVORABLY FORWARDED BY THE  
SUBCOMMITTEE ON HEALTH ON NOVEMBER 4, 2021)

117TH CONGRESS  
1ST SESSION

# H. R. 1193

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, shall establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

---

### IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 22, 2021

Mr. BARR introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, shall establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Cardiovascular Ad-  
3 vances in Research and Opportunities Legacy Act”.

4 **SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-**  
5 **SEARCH.**

6 Subpart 2 of part C of title IV of the Public Health  
7 Service Act (42 U.S.C. 285b et seq.) is amended by insert-  
8 ing after section 424C (42 U.S.C. 285b–7c) the following:

9 **“SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-**  
10 **SEARCH.**

11 “(a) IN GENERAL.—The Director of the National In-  
12 stitutes of Health, in consultation with the Director of the  
13 Institute, shall support or conduct research regarding val-  
14 vular heart disease.

15 “(b) SUPPORT GUIDELINES.—The distribution of  
16 funding authorized under subsection (a) may be used to  
17 pursue the following outcomes:

18 “(1) Using precision medicine and advanced  
19 technological imaging to generate data on individ-  
20 uals with valvular heart disease.

21 “(2) Identifying and developing a cohort of in-  
22 dividuals with valvular heart disease and available  
23 data.

24 “(3) Corroborating data generated through clin-  
25 ical trials to develop a prediction model to distin-  
26 guish individuals at high risk for sudden cardiac ar-

1 rest or sudden cardiac death from valvular heart dis-  
2 ease.

3 “(4) For other outcomes needed to acquire nec-  
4 essary data on valvular heart disease.

5 “(c) MITRAL VALVE PROLAPSE WORKSHOP.—Not  
6 later than one year after the date of the enactment of this  
7 section, the Director of the Institute shall convene a work-  
8 shop composed of subject matter experts and stakeholders  
9 to identify research needs and opportunities to develop  
10 prescriptive guidelines for treatment of individuals with  
11 mitral valve prolapse.

12 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the  
13 purpose of carrying out this section, there is authorized  
14 to be appropriated \$20,000,000 for each of fiscal years  
15 2022 through 2026.”.

16 **SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL**  
17 **AND PREVENTION.**

18 Part B of title III of the Public Health Service Act  
19 (42 U.S.C. 243 et seq.) is amended by inserting after sec-  
20 tion 312 the following section:

21 **“SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A**  
22 **RESULT OF VALVULAR HEART DISEASE.**

23 “(a) IN GENERAL.—The Secretary, acting through  
24 the Director of the Centers for Disease Control and Pre-  
25 vention, may carry out projects to increase education,

1 awareness, or diagnosis of valvular heart disease and to  
2 reduce the incidence of sudden cardiac death caused by  
3 valvular heart disease. Such projects may be carried out  
4 by the Secretary directly or through awards of grants or  
5 contracts to public or nonprofit private entities. The Sec-  
6 retary may directly (or through such awards) provide tech-  
7 nical assistance with respect to the planning, development,  
8 and operation of such projects.

9 “(b) CERTAIN ACTIVITIES.—Upon availability of ap-  
10 plicable data, projects carried out under subsection (a)  
11 may include—

12 “(1) continuing the activities at the Division for  
13 Heart Disease and Stroke Prevention, including  
14 those related to valvular heart disease; and

15 “(2) broadening the awareness of the public  
16 concerning the risk factors for, the symptoms of,  
17 and the public health consequences of valvular heart  
18 disease; and

19 “(3) enhancing surveillance of out-of-hospital  
20 cardiac arrests to improve patient outcomes.

21 “(c) GRANT PRIORITIZATION.—The Secretary may,  
22 in awarding grants or entering into contracts pursuant to  
23 subsection (a), give priority to entities seeking to carry  
24 out projects that target populations most impacted by val-  
25 vular heart disease.

1           “(d) COORDINATION OF ACTIVITIES.—The Secretary  
2 shall ensure that activities under this section are coordi-  
3 nated, as appropriate, with other agencies of the Public  
4 Health Service that carry out activities regarding valvular  
5 heart disease.

6           “(e) BEST PRACTICES.—The Secretary, acting  
7 through the Director of the Centers for Disease Control  
8 and Prevention, shall—

9                   “(1) collect and analyze the findings of research  
10           conducted with respect to valvular heart disease; and

11                   “(2) taking into account such findings, publish  
12           on the website of the Centers for Disease Control  
13           and Prevention best practices for physicians and  
14           other health care providers who provide care to indi-  
15           viduals with valvular heart disease.”.